IN8bio, Inc. - INAB STOCK NEWS

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced the successful results of its non-signaling gamma-delta CAR-T platform (nsCAR), which targets leukemic cells while preserving healthy B cells. Presented at the 6th CAR-TCR Summit Europe, the nsCAR platform exhibited a greater than 15x difference in cytotoxicity between leukemic cells and healthy B cells. This innovative approach promises to enhance CAR technology for previously 'undruggable' tumors, including acute myeloid leukemia (AML). IN8bio aims to expand its applications in solid tumors, with future clinical trials planned for this promising technology.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced that CEO William Ho will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 1:30 pm ET. This presentation aims to highlight IN8bio's innovative gamma-delta T cell therapies for solid and liquid tumors. The event will be available live and as a replay on the company's website. IN8bio is conducting Phase 1 trials for its lead candidates, INB-200 and INB-100, and is set to launch a Phase 2 trial for INB-400 in glioblastoma, following IND clearance in late 2022. For further information, visit IN8bio's website.

IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will present at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 12:00pm ET. The conference will showcase IN8bio’s innovative gamma-delta T cell therapies for solid and liquid tumors, emphasizing their unique ability to differentiate healthy from diseased tissues. Currently, IN8bio is conducting two Phase 1 clinical trials for its leading candidates: INB-200 targeting glioblastoma and INB-100 for leukemia patients. A Phase 2 trial, INB-400, is also set to begin post-IND clearance. For further details, visit IN8bio.com.

IN8bio, a clinical-stage biopharmaceutical company, reported promising initial data from its Phase 1 trial of INB-200 in newly diagnosed glioblastoma multiforme (GBM). All three patients in Cohort 2 exceeded the median progression-free survival of seven months, with responses ongoing beyond 1.5 years. The company aims to start a Phase 2 trial of INB-400 by Q3 2023 and anticipates submitting an IND for INB-410 in 2H 2023. No serious adverse events related to treatment have been reported, indicating a favorable safety profile.

IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical leader in gamma-delta T cell therapies, announced that CEO William Ho will present at the Biotech Showcase 2023 on January 9, 2023. The company will participate in a panel discussion on innovative gene and cell therapy approaches on January 10. This event will occur at the Hilton San Francisco Union Square, coinciding with the 41st Annual J.P. Morgan Healthcare Conference from January 9-11, 2023. IN8bio is currently advancing several clinical trials for its lead products targeting glioblastoma and leukemia.

IN8bio announced positive results from the Phase 1 trial of INB-100, a gamma-delta T cell therapy for hematological malignancies. Patients in the first cohort showed durable responses, remaining progression-free for over 2.5 years. Notably, 4 patients treated at the first dose level have maintained remission, with no dose-limiting toxicities reported. Enrollment for Cohort 2 has begun, with updates anticipated in Q2 2023. The results highlight INB-100's potential to improve cure rates in high-risk acute myeloid leukemia patients undergoing haploidentical stem cell transplantation.

IN8bio has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of INB-400, targeting newly diagnosed glioblastoma. The trial aims to assess the safety and efficacy of genetically modified DeltEx drug-resistant immunotherapy cells at various U.S. medical centers. This milestone marks IN8bio's first company-sponsored IND and sets the stage for further exploration of its DeltEx platform across solid tumor cancers. A conference call will be held on December 12 to discuss updated data from the ongoing Phase 1 trial of INB-100.

IN8bio, Inc. (Nasdaq: INAB) reported significant progress in its third quarter 2022 updates. The Phase 1 trial of INB-100 in leukemia patients showed durable morphologic complete responses with no dose-limiting toxicities. The company raised $9.8 million through an equity offering, boosting its cash position to $27.6 million. Additionally, IN8bio partnered with the Dunbar CAR T-Cell Program for INB-400 GMP production and expanded its R&D efforts, although it reported a net loss of $7.4 million for the quarter.

IN8bio, Inc. (Nasdaq: INAB) announced promising early results from its ongoing Phase 1 trial of INB-100, targeting high-risk acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplant. Notably, all three patients in Cohort 1 are alive and progression-free, with response durations exceeding 12 to 26.5 months. The safety profile remains manageable, with no dose-limiting toxicities observed. Updated data will be presented at the upcoming ASH Annual Meeting on December 11, 2022, highlighting the potential of INB-100 to impact AML treatment paradigms.